Press release
Graves Ophthalmopathy Pipeline 2024: Clinical Trials Assessment, FDA Approvals, Therapies, Involved by DelveInsight | Novartis, AdvanceCor, Apitope, Worg Pharma, AV7 Ltd.
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Graves Ophthalmopathy pipeline constitutes 10+ key companies continuously working towards developing 10+ Graves Ophthalmopathy treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight."Graves Ophthalmopathy Pipeline Insight, 2024 [https://www.delveinsight.com/sample-request/graves-ophthalmopathy-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Graves Ophthalmopathy Market.
The Graves Ophthalmopathy Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Some of the key takeaways from the Graves Ophthalmopathy Pipeline Report:
*
Companies across the globe are diligently working toward developing novel Graves Ophthalmopathy treatment therapies with a considerable amount of success over the years.
*
Graves Ophthalmopathy companies working in the treatment market are Immunovant Sciences GmbH, Horizon Pharma USA, Inc., Viridian Therapeutics, Inc., Tourmaline Bio, Inc., ACELYRIN Inc., Hoffmann-La Roche, Horizon Therapeutics USA, Inc., Lassen Therapeutics Inc., Novartis, Sling Therapeutics, Inc., Lassen Therapeutics, and others, are developing therapies for the Graves Ophthalmopathy treatment
*
Emerging Graves Ophthalmopathy therapies in the different phases of clinical trials are- Batoclimab (IMVT 1401), RVT-1401, Teprotumumab, VRDN-001 10 mg/kg Drug, TOUR006 - 20 MG, IBI311, lonigutamab, Satralizumab, TEPEZZA, LASN01, CFZ533, linsitinib, LASN01, and others are expected to have a significant impact on the Graves Ophthalmopathy market in the coming years.
*
In June 2024, US-based biotechnology firm Viridian Therapeutics has revealed plans to initiate two Phase III clinical trials for the anti-IGF-1R antibody, VRDN-003, targeting moderate-to-severe thyroid eye disease (TED). The trials, named REVEAL-1 and REVEAL-2, will evaluate the efficacy and safety of subcutaneous doses of VRDN-003 in patients with active and chronic TED, respectively.
*
In April 2024, Amgen (NASDAQ:AMGN) announced plans to submit a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for teprotumumab, a fully human monoclonal antibody and targeted inhibitor of the insulin-like growth factor-1 receptor (IGF-1R), intended for the treatment of moderate to severe Thyroid Eye Disease (TED) in adults. TED is a serious, progressive, debilitating, and potentially vision-threatening autoimmune disease that can cause proptosis (eye bulging), diplopia (double vision), eye pain, redness, and swelling. If approved, teprotumumab would be the first and only medication approved for TED in the European Union.
*
In August 2023, The US Food and Drug Administration (FDA) has approved Tourmaline Bio's investigational new drug (IND) application, allowing the commencement of a Phase IIb trial for TOUR006 aimed at treating thyroid eye disease (TED), also known as Graves' ophthalmopathy. This upcoming study will evaluate the effectiveness of 20mg and 50mg doses of TOUR006 compared to a placebo in patients with moderate to severe TED who are currently in the active phase of the disease.
Graves Ophthalmopathy Overview
Graves' Ophthalmopathy, also known as Thyroid Eye Disease (TED) or Graves' Orbitopathy, is an autoimmune inflammatory disorder associated with thyroid disease, particularly Graves' disease. It affects the muscles and other tissues around the eyes, leading to various symptoms and complications.
Get a Free Sample PDF Report to know more about Graves Ophthalmopathy Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/graves-ophthalmopathy-pipeline-insight [https://www.delveinsight.com/report-store/graves-ophthalmopathy-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Emerging Graves Ophthalmopathy Drugs Under Different Phases of Clinical Development Include:
*
Batoclimab (IMVT 1401): Immunovant Sciences
*
RVT-1401: Immunovant Sciences GmbH
*
Teprotumumab: Horizon Pharma USA, Inc.
*
VRDN-001 10 mg/kg Drug: Viridian Therapeutics, Inc.
*
Batoclimab: Immunovant Sciences GmbH
*
TOUR006 - 20 MG: Tourmaline Bio, Inc.
*
IBI311: Innovent Biologics (Suzhou) Co. Ltd.
*
lonigutamab: ACELYRIN Inc.
*
Satralizumab: Hoffmann-La Roche
*
TEPEZZA: Horizon Therapeutics USA, Inc.
*
LASN01: Lassen Therapeutics Inc.
*
CFZ533: Novartis
*
linsitinib: Sling Therapeutics, Inc.
*
LASN01: Lassen Therapeutics
Graves Ophthalmopathy Route of Administration
Graves Ophthalmopathy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
*
Oral
*
Intravenous
*
Subcutaneous
*
Parenteral
*
Topical
Graves Ophthalmopathy Molecule Type
Graves Ophthalmopathy Products have been categorized under various Molecule types, such as
*
Recombinant fusion proteins
*
Small molecule
*
Monoclonal antibody
*
Peptide
*
Polymer
*
Gene therapy
Graves Ophthalmopathy Pipeline Therapeutics Assessment
*
Graves Ophthalmopathy Assessment by Product Type
*
Graves Ophthalmopathy By Stage and Product Type
*
Graves Ophthalmopathy Assessment by Route of Administration
*
Graves Ophthalmopathy By Stage and Route of Administration
*
Graves Ophthalmopathy Assessment by Molecule Type
*
Graves Ophthalmopathy by Stage and Molecule Type
DelveInsight's Graves Ophthalmopathy Report covers around 10+ products under different phases of clinical development like
*
Late-stage products (Phase III)
*
Mid-stage products (Phase II)
*
Early-stage product (Phase I)
*
Pre-clinical and Discovery stage candidates
*
Discontinued & Inactive candidates
*
Route of Administration
Further Graves Ophthalmopathy product details are provided in the report. Download the Graves Ophthalmopathy pipeline report to learn more about the emerging Graves Ophthalmopathy therapies [https://www.delveinsight.com/sample-request/graves-ophthalmopathy-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Some of the key companies in the Graves Ophthalmopathy Therapeutics Market include:
Key companies developing therapies for Graves Ophthalmopathy are - Novartis, AdvanceCor, Apitope, Worg Pharmaceuticals, AV7 Limited, and others.
Graves Ophthalmopathy Pipeline Analysis:
The Graves Ophthalmopathy pipeline report provides insights into
*
The report provides detailed insights about companies that are developing therapies for the treatment of Graves Ophthalmopathy with aggregate therapies developed by each company for the same.
*
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Graves Ophthalmopathy Treatment.
*
Graves Ophthalmopathy key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
*
Graves Ophthalmopathy Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
*
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Graves Ophthalmopathy market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Graves Ophthalmopathy drugs and therapies [https://www.delveinsight.com/sample-request/graves-ophthalmopathy-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Graves Ophthalmopathy Pipeline Market Strengths
*
The recent US FDA approval of Horizon's TEPEZZA has accelerated the research and development of GO.
*
Recent efforts to increase patient and clinician awareness of GO, with various awareness campaigns, are expected to increase early diagnosis and treatment of GO.
Graves Ophthalmopathy Pipeline Market Opportunities
*
Designing an effective molecule with an intended delivery mode that is matched to the intended target compartment is a necessary first step in ocular drug discovery programs.
*
Lack of availability of disease-modifying treatment for chronic patients, who have a significant impact on their emotional and social well-being.
Scope of Graves Ophthalmopathy Pipeline Drug Insight
*
Coverage: Global
*
Key Graves Ophthalmopathy Companies: Immunovant Sciences GmbH, Horizon Pharma USA, Inc., Viridian Therapeutics, Inc., Tourmaline Bio, Inc., ACELYRIN Inc., Hoffmann-La Roche, Horizon Therapeutics USA, Inc., Lassen Therapeutics Inc., Novartis, Sling Therapeutics, Inc., Lassen Therapeutics, and others
*
Key Graves Ophthalmopathy Therapies: Batoclimab (IMVT 1401), RVT-1401, Teprotumumab, VRDN-001 10 mg/kg Drug, TOUR006 - 20 MG, IBI311, lonigutamab, Satralizumab, TEPEZZA, LASN01, CFZ533, linsitinib, LASN01, and others
*
Graves Ophthalmopathy Therapeutic Assessment: Graves Ophthalmopathy current marketed and Graves Ophthalmopathy emerging therapies
*
Graves Ophthalmopathy Market Dynamics: Graves Ophthalmopathy market drivers and Graves Ophthalmopathy market barriers
Request for Sample PDF Report for Graves Ophthalmopathy Pipeline Assessment and clinical trials [https://www.delveinsight.com/sample-request/graves-ophthalmopathy-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Table of Contents
1. Graves Ophthalmopathy Report Introduction
2. Graves Ophthalmopathy Executive Summary
3. Graves Ophthalmopathy Overview
4. Graves Ophthalmopathy- Analytical Perspective In-depth Commercial Assessment
5. Graves Ophthalmopathy Pipeline Therapeutics
6. Graves Ophthalmopathy Late Stage Products (Phase II/III)
7. Graves Ophthalmopathy Mid Stage Products (Phase II)
8. Graves Ophthalmopathy Early Stage Products (Phase I)
9. Graves Ophthalmopathy Preclinical Stage Products
10. Graves Ophthalmopathy Therapeutics Assessment
11. Graves Ophthalmopathy Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Graves Ophthalmopathy Key Companies
14. Graves Ophthalmopathy Key Products
15. Graves Ophthalmopathy Unmet Needs
16 . Graves Ophthalmopathy Market Drivers and Barriers
17. Graves Ophthalmopathy Future Perspectives and Conclusion
18. Graves Ophthalmopathy Analyst Views
19. Appendix
20. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=graves-ophthalmopathy-pipeline-2024-clinical-trials-assessment-fda-approvals-therapies-involved-by-delveinsight-novartis-advancecor-apitope-worg-pharma-av7-ltd]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Graves Ophthalmopathy Pipeline 2024: Clinical Trials Assessment, FDA Approvals, Therapies, Involved by DelveInsight | Novartis, AdvanceCor, Apitope, Worg Pharma, AV7 Ltd. here
News-ID: 3562111 • Views: …
More Releases from ABNewswire

NMIBC Market to Experience Notable Growth in Forecast Span by 2034, DelveInsight …
The Key Non-Muscle Invasive Bladder Cancer Companies in the market include - Ferring Pharmaceuticals/FKD Therapies Oy, ImmunityBio, CG Oncology, Pfizer, UroGen Pharma, Janssen Research & Development, LLC, Protara Therapeutics, Pfizer, AstraZeneca, ImmunityBio, Inc., Janssen Research & Development, Tollys, Aura Biosciences, Vaxiion Therapeutics, Incyte Corporation, Janssen Pharmaceuticals, Theralase Technologies, BristolMyers Squibb, Asieris Pharmaceuticals, and others.
DelveInsight's "Non-Muscle Invasive Bladder Cancer Market Insights, Epidemiology, and Market Forecast-2034 report offers an in-depth understanding of…

Plaque Psoriasis Market Insights Highlight Expanding Outlook Till 2034, DelveIns …
The Key Plaque Psoriasis Companies in the market include - Dermavant Sciences GmbH, IQVIA Biotech, UCB Biopharma SRL, Parexel, Samsung Bioepis Co., Ltd, Durect, Astellas, Biogen, Dow Pharmaceutical Sciences, Shire, Zalicus, AbbVie, Santalis Pharmaceuticals Inc, Maruho Co Ltd, Novartis, AstraZeneca, Pfizer, and others.
DelveInsight's "Plaque Psoriasis Market Insights, Epidemiology, and Market Forecast-2034 report offers an in-depth understanding of the Plaque Psoriasis, historical and forecasted epidemiology as well as the Plaque Psoriasis…

Acute Myeloid Leukemia Market to Evolve Rapidly Over the Next Decade by 2034, De …
The Key Acute Myeloid Leukemia Companies in the market include - SystImmune, Jasper Therapeutics, Chimerix, Akeso Biopharma Co., Ltd., Syros Pharmaceuticals, TC Biopharm, Stemline Therapeutics, Orca Bio, Gilead Sciences, GlycoMimetics, and others.
The Acute Myeloid Leukemia market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Acute Myeloid Leukemia pipeline products will significantly revolutionize the Acute Myeloid Leukemia market dynamics.
DelveInsight's…

Pancreatic Cancer Market Positioned for Accelerated Development Through 2034, De …
The Key Pancreatic Cancer Companies in the market include - AstraZeneca, Merck Sharp & Dohme, Actuate Therapeutics, Dragonfly Therapeutics, Keymed B, Tango Therapeutics, Atara Biotherapeutics, Keymed Biosciences Co.Ltd, Carisma Therapeutics Inc, Cue Biopharma, Bold Therapeutics, Purple Biotech Ltd, ENB Therapeutics, Gritstone bio, AstraZeneca, Candel Therapeutics, Alligator Bioscience, FibroGen, Novartis AG, AB Science, Eleison Pharmaceuticals, and others.
The Pancreatic Cancer market is expected to surge due to the disease's increasing prevalence and…
More Releases for Graves
Graves' Disease Market New Product Development & Latest Trends
Introduction
Graves' disease is an autoimmune disorder that causes hyperthyroidism, or overproduction of thyroid hormones, through antibodies that stimulate the thyroid gland. It is among the most common thyroid-related autoimmune conditions, disproportionately affecting women between 30-60 years of age. Beyond metabolic complications such as weight loss, heat intolerance, and palpitations, Graves' disease can cause thyroid eye disease (TED), which impairs vision and quality of life.
For decades, treatment has relied on antithyroid…
Graves Ophthalmopathy Pipeline Therapeutics Assessment Report 2024 (Updated)
DelveInsight's, "Graves Ophthalmopathy Pipeline Insight 2024" report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Graves Ophthalmopathy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore our latest breakthroughs in Graves Ophthalmopathy Research. Learn more about…
Search for graves and burials in Minsk
If you are looking for information about the location of the grave in Minsk or other regions of Belarus, the company https://verimby.com +375293887408 (Viber); +375447498518 (WhatsApp) offers professional assistance in this important matter. We specialize in finding burial sites, providing detailed data and providing support in restoring lost ties with the past, creating a family tree, even if you are in another country.
Why can the search for graves in Belarus…
Graves' Disease Treatment Market Size, Drugs, Companies 2034 | DelveInsight
Graves' Disease Treatment Market is projected to witness substantial growth over the next few years, driven by advancements in treatment modalities and increasing awareness of the condition. The pipeline for Graves' Disease Therapeutics includes promising candidates that aim to not only treat acute attacks but also prevent recurrence.
DelveInsight's "Graves' Disease Market Insights, Epidemiology and Market Forecast - 2034" report delivers an in-depth understanding of the Graves' Disease, historical and…
Japan Graves' disease Market Size & Growth Analysis Report, 2019-2025
Japan Graves' disease market is growing at a CAGR of around 4.7% during the forecast period. According to the WHO, around 10.1% of the country's population is suffering from diabetes, among which, the individuals suffering from type-1 diabetes are more prone to develop Grave's disease in the near future. According to IDF, around 2.2 per thousand children and adolescents aged 14 years and below are suffering from type-1 diabetes in…
Global Graves Disease Market Status and Outlook (2020-2025)
Global Info Research offers a latest published report on Graves Disease Analysis and Forecast 2020-2025 delivering key insights and providing a competitive advantage to clients through a detailed report. This report focuses on the key global Graves Disease Concentrate players, to define, describe and analyze the value, market share, market competition landscape, SWOT analysis and development plans in next few years.
Click to view the full report TOC, figure and tables:
https://www.globalinforesearch.com/reports/515950/graves-disease
Market…